Colombia Targets Trachoma Elimination as PAHO Reports 200,000 Still Need Care

Key facts

According to details released by PAHO, public health authorities in Colombia are accelerating fieldwork under the regional Initiative for the Elimination of Trachoma in the Americas to address an active disease burden affecting over 200,000 people. The high-risk zones are predominantly located within the dense rainforest geography of Colombia's Amazonian departments, including Vaupés, Guainía, and Amazonas, where healthcare delivery presents extreme logistical challenges.

To reach populations living along distant tributaries of the Amazon and Orinoco basins, multi-disciplinary health teams are utilizing motorized canoes, light aircraft, and extended foot treks. These teams carry essential medical supplies, including oral azithromycin treatments provided through global donation channels, diagnostic instruments, and portable surgical equipment.

The intervention strategy centers on deploying the standardized WHO protocol known as SAFE. Medical personnel perform trichiasis surgery to reverse inward-facing eyelashes in patients with advanced stage disease, preventing irreversible corneal scarring. Simultaneously, health workers carry out mass drug administration campaigns, administering single-dose oral antibiotics to entire village populations to clear background bacterial reservoirs.

In tandem with clinical management, public health promoters are conducting community hygiene workshops adapted to local indigenous cultures and languages. These programs focus on encouraging frequent facial washing among children, who serve as the primary reservoir for infection transmission. Field teams are also evaluating local water sources and working alongside municipal authorities to implement basic sanitation improvements designed to suppress fly vectors that carry the bacteria from person to person.

Why it matters

The persistent footprint of trachoma in Colombia underscores the deep health equities gap dividing urban centers from marginalized rural and indigenous territories. Because trachoma flourishes in conditions of extreme poverty, crowded living environments, and severe water scarcity, its prevalence acts as a direct indicator of socio-economic vulnerability. Preventing the progression of trachoma from mild conjunctival inflammation to complete blindness is essential for safeguarding individual autonomy and preserving local economic livelihoods in remote regions.

When adult family members succumb to irreversible blindness caused by advanced trichiasis, household structures face catastrophic economic strain. Children, particularly young girls, are frequently withdrawn from school to serve as full-time caregivers for blind relatives, perpetuating generational cycles of poverty and educational deprivation. By eliminating active infection chains across the Amazon basin, public health programs protect working-age adults, maintain educational access for indigenous youth, and alleviate structural strain on regional healthcare networks.

On a broader scale, Colombia’s progress serves as a benchmark for the Pan American Health Organization’s ambition to eradicate targeted neglected tropical diseases across Latin America and the Caribbean by 2030. Successful elimination in complex rainforest environments demonstrates that rigorous public health delivery is achievable even under extreme logistical constraints. Conversely, any persistent reservoirs in Colombia risk recontaminating neighboring frontier regions in Brazil and Peru, highlighting the cross-border imperative of sustained disease surveillance.

Trachoma is an ancient infectious disease caused by specific serotypes of the bacterium *Chlamydia trachomatis*. Infection is transmitted through direct personal contact with eye and nose discharges from infected individuals, indirect contact via contaminated clothing and towels, or mechanical transmission by eye-seeking flies, primarily *Musca sorbens*. Repeated bacterial reinfections over childhood and adolescence induce chronic inflammation of the conjunctiva, the lining inside the eyelid. Over time, this recurring inflammation creates severe scarring that pulls the eyelid margins inward, causing the eyelashes to rub against the cornea—a painful condition known as trachomatous trichiasis. Left untreated, the continuous mechanical abrasion opaque-ifies the cornea, resulting in irreversible vision loss and total blindness.

To combat the disease, the World Health Organization endorsed the SAFE strategy in 1993, an integrated approach combining Surgery, Antibiotics, Facial cleanliness, and Environmental improvement. Under international standards established by the World Health Assembly, a nation achieves official WHO validation of elimination of trachoma as a public health problem when two key criteria are satisfied: first, the prevalence of active trachoma (trachomatous inflammation—follicular, or TF) remains below 5% among children aged 1 to 9 years in every formerly endemic district; second, the prevalence of trachomatous trichiasis (TT) unmanaged by the health system remains below 0.2% among individuals aged 15 years and older.

Across the Americas, trachoma was historically widespread across tropical and subtropical zones. Through urban development, expanded water access, and dedicated public health campaigns, most countries in the region successfully contained or eradicated the disease during the 20th century. However, persistent endemic foci remained in four countries: Brazil, Colombia, Guatemala, and Mexico. Mexico became the first nation in the Americas to receive formal WHO validation for eliminating trachoma as a public health problem in 2017, setting a precedent for its neighboring states. The Pan American Health Organization has since intensified technical assistance to Colombia and neighboring countries to close the remaining gaps under its Disease Elimination Initiative.

Reaction

Public health experts and technical advisors from the Pan American Health Organization emphasized that while Colombia has made measurable strides in identifying endemic clusters, maintaining momentum in the Amazon region requires persistent logistical and financial commitments. PAHO representatives underscored that technical assistance will continue to focus on strengthening epidemiological surveillance, supporting laboratory diagnostics, and ensuring robust supply chains for mass drug administration.

Indigenous community leaders and regional leaders from Amazonian indigenous federations have expressed support for the health campaigns while emphasizing that antibiotic distribution must be matched by structural government investments. Representatives of local indigenous councils have repeatedly pointed out that drug distribution offers a temporary remedy if communities continue to lack piped potable water, functional sewage systems, and routine primary healthcare infrastructure.

The Colombian Ministry of Health and the National Institute of Health (Instituto Nacional de Salud) are expected to present updated field data at upcoming regional public health summits. International health partners and philanthropic organizations involved in the International Trachoma Initiative have reaffirmed their commitment to providing donated azithromycin, stressing that global targets for neglected tropical disease elimination cannot be met without fully clearing persistent reservoirs in the Amazon basin.

What we don't know yet

Despite the global data released by PAHO, several operational details regarding the current scope of the disease in Colombia remain undisclosed. The precise breakdown of the 200,000 affected individuals across specific municipal jurisdictions and indigenous *resguardos* (reservoirs/territories) has not been fully detailed in the current public summary. Without disaggregated district-level prevalence figures, external observers cannot evaluate which specific health districts are closest to achieving the under-5% active infection threshold required for WHO validation.

Furthermore, the full extent of environmental challenges—such as climate-driven flooding along Amazonian river corridors—on fly vector populations and local water access remains an active variable. It is also unclear how quickly municipal water supply projects will be completed in isolated indigenous settlements to sustain the environmental component of the SAFE strategy over the long term. Finally, public health authorities have not yet announced a definitive timetable for when Colombia intends to submit its final elimination dossier to the WHO Dossier Review Group.

What to watch

In the coming months, several key milestones will indicate the progress of Colombia's elimination campaign. Observers should track the rollout of scheduled mass drug administration cycles conducted by regional health secretariats across high-priority districts in the Amazonian departments of Vaupés, Guainía, and Amazonas.

Additionally, epidemiological evaluation surveys conducted by Colombia's National Institute of Health will serve as critical indicators. These formal field surveys, which assess active infection rates among children aged 1 to 9, will determine whether specific health districts qualify to transition from active mass treatment into post-treatment surveillance phases.

At the international level, public health policy tracking will focus on PAHO's annual directorship reports and the proceedings of the WHO Alliance for the Global Elimination of Trachoma by 2030 (GET2030). Concrete legislative and budget allocations by the Colombian government toward rural water infrastructure in indigenous territories will also serve as a key metric for determining whether elimination can be sustained permanently once antibiotic cycles end.

This report is based on original reporting published by the Pan American Health Organization (PAHO/WHO).